Search

Search Constraints

You searched for: Author/Creator Paschen, Annette

Search Results

3. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. (December 2021)

4. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. (January 2022)

6. ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope. Issue 2 (27th November 2019)

7. Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype. Issue 11 (1st November 2022)

8. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors. Issue 9 (11th July 2022)

9. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity. Issue 6 (13th June 2022)

10. Direct RIG‐I activation in human NK cells induces TRAIL‐dependent cytotoxicity toward autologous melanoma cells. Issue 7 (9th January 2019)